Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Commercial

Novo hits back at rivals with cut-price Wegovy subscriptions

 March 31, 2026

Pharmaphorum

Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.

CommercialMetabolic & GLP-1Read full story

Post navigation

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout →
← S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com